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Abstract
Background and aims: Right ventricular pacing may lead to heart failure (HF). Upgrades from
pacemakers to cardiac resynchronization therapy (CRT) were excluded from most randomized,
controlled trials. We sought to determine the long-term outcomes of upgrading from pacemak-
ers to CRT with (CRT-D) or without (CRT-P) defibrillation in patients with no history of sustained
ventricular arrhythmias.
Methods and results: In this observational study, clinical events were quantified in relation to the
type of implant (de novoor upgrade) and device type at upgrade (CRT-P orCRT-D). Patients under-
went CRT implantation (n = 1,545; 1,314 [85%] de novo implants and 231 [15%] upgrades) over a
median of 4.6 years [interquartile range: 2.4–7.0]. In analyses of crude event rates, upgrades had a
higher total mortality (adjusted hazard ratio [aHR]: 1.33; 95% confidence interval [CI] 0.10–1.61),
a higher total mortality or HF hospitalization (aHR: 1.26; 95% CI 1.05–1.51), but similar mortal-
ity or hospitalization for major adverse cardiac events (MACEs, aHR: 1.15; 95% CI 0.96–1.38).
No group differences emerged in any of these endpoints after propensity score matching. After
inverse probabilityweighting in upgrades, total mortality (HR: 0.55; 95%CI 0.36–0.73), total mor-
tality orHF hospitalization (HR: 0.56; 95%CI 0.34–0.79), and totalmortality or hospitalization for
MACEs (HR: 0.61; 95%CI 0.40–0.82) were lower after CRT-D than after CRT-P.
Conclusion: Upgrading from pacemakers to CRT was associated with a similar long-term risk of
mortality and morbidity to de novo CRT. After upgrade, CRT-D was associated with a lower mor-
tality than CRT-P.
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1 INTRODUCTION
Cardiac resynchronization therapy (CRT) is a standard treatment for
selected patients with heart failure, impaired left ventricular (LV) func-
tion, and a wide QRS complex.1 Most randomized, controlled trials of
CRT have excluded patients with previously implanted devices and,
therefore, the randomized, controlled evidence base for CRT is limited
to de novo CRT. Up to 27% of patients attending a typical pacemaker
clinic have heart failure (HF).2
Right ventricular (RV) pacing is life-saving in patients with brady-
arrhythmia, but it induces a pattern of ventricular activation akin to
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a left bundle branch block. This causes (LV) mechanical dyssynchrony,
which is now known to precipitate HF. The first clinical evidence for
a detrimental effect of RV pacing emerged from randomized trials
comparing the effects of atrial versus RV pacing in patients with sick
sinus syndrome, in which up to 40% of patients developed HF with
RV pacing.3,4 In the Dual Chamber and VVI Implantable Defibrillator
(DAVID) study5,6 and theModeSelectionTrial (MOST),7 RVpacingwas
also associated with a higher risk of HF hospitalization.
Several studies have explored the acute and short-term effects of
upgrading from RV pacing to CRT.8–13We, as others, have shown that
the symptomatic response12,14 and outcomes15 of upgrading to CRT
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are similar to de novo CRT. The 2012 ACCF/AHA/HRS (American Col-
lege of Cardiology Foundation/AmericanHeart Association Task Force
on Practice Guidelines/the Heart Rhythm Society) guideline16 recom-
mended a CRT upgrade at generator replacement if LV function is
severely impaired and the expected pacing requirement is ≥40%.17
An observational study of patients with implanted pacemakers or
implantable cardioverter defibrillators (ICDs) upgraded to either CRT-
pacemaker (CRT-P) or CRT-defibrillator (CRT-D)18 provided the evi-
dence base for the 2016 European Society of Cardiology guideline
recommendation to offer CRT upgrade to patients with HF. While
upgrading was adopted in clinical practice even before such recom-
mendations emerged,19,20 the clinical question remains as to whether
CRT-D should be used in preference to CRT-P at the time of upgrading
patients with pacemakers and without prior ventricular arrhythmias.
In the present study, we have compared long-term outcomes of CRT-D
and CRT-D, implanted either de novo or as an upgrade from pacemak-
ers over a period of 16 years.
2 METHODS
The study population consisted of patients undergoing a successful
CRT device implantation for in the period from October 2000 to
January 2016 at two centers (Queen Elizabeth Hospital and Good
HopeHospital, Birmingham,UnitedKingdom). Patientswith aprevious
ICD implant or a sustained ventricular arrhythmia warranting upgrade
to CRT-D were excluded. Some patients (n = 394) were included in a
previous study.15 The present study increases the number of patients
and the length of follow-up.
Device choice was influenced by the National Institute of Clini-
cal Excellence guidelines, which in 2007 recommended CRT-P rather
than CRT-D for patients with nonischemic cardiomyopathy and indi-
cations for CRT. With a subsequent guideline change in 2014 recom-
mending CRT-D in nonischemic cardiomyopathy,21 the proportion of
CRT-D recipients increased thereafter. The studywas approved by the
local Ethics Committee or the local Clinical Audit Departments, which
waived the requirement for patient informed consent for audits of clin-
ical care delivery and outcomes. The study conforms with the Declara-
tion of Helsinki.
The diagnosis of HF was made on the basis of clinical features
plus echocardiographic evidence of LV systolic dysfunction. The etiol-
ogy of HF was based on the findings from clinical history (myocardial
infarction, coronary revascularization) and/or investigation (e.g., car-
diovascular magnetic resonance and nuclear imaging). Patients with
hypertrophic or restrictive cardiomyopathy, primary valvular disease,
sarcoidosis, amyloidosis, or myocarditis were excluded. Patients who
were recruited to clinical trials were also excluded.
2.1 Device therapy
Device implantation was undertaken using standard transvenous
techniques under local anesthesia and intravenous sedation. After
implantation, patients were followed-up in dedicated device therapy
clinics. Device optimization using transmitral Doppler-directed opti-
mization of atrioventricular delay using an iterative technique was
undertaken up to 2013, when routine echocardiographic optimization
F IGURE 1 Primary and secondary endpoints in de novo implants and
upgrades. Kaplan-Meier survival curves for clinical outcomes accord-
ing whether patients had a de novo implant or an upgrade. CRT-
D = cardiac resynchronization therapy-defibrillation; CRT-P = cardiac
resynchronization therapy-pacing; HF = heart failure; MACE = major
adverse cardiovascular events [Color figure can be viewed at wileyon-
linelibrary.com]
was no longer deemed necessary on the basis of emerging evidence.
Thereafter, optimization was only undertaken in symptomatic nonre-
sponders. In patients in sinus rhythm, backup atrial pacing was set at
60 beats/min, and the pacingmodewas set to DDDRwith an interven-
tricular delay of 0–20ms (LV stimulation first). In patients with perma-
nent atrial fibrillation, RV and LV leads were implanted and a CRT gen-
erator was used, plugging the atrial port and programming to a either
VVIR or ventricular triggered modes, according to physician's discre-
tion. Atrioventricular junction ablation was undertaken according to
physicians’ discretion.
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TABLE 1 Baseline characteristics
All De novo Upgrade P* Upgrade to CRT-D Upgrade to CRT-P P*
N 1,545 1,314 231 61 170
Sex (male), n (%) 1,137 (73.59) 964 (73.36) 173 (74.89) 0.627 44 (72.13) 129 (75.88) 0.562
Age, years 72.1± 10.8 71.5± 10.8 75.5± 10.2 <0.001 71.9± 9.5 76.8± 10.2 0.001
≤59 203 (13.14) 185 (14.08) 18 (7.79) <0.001 7 (11.48) 11 (6.47) 0.010
60–69 388 (25.11) 346 (26.33) 42 (18.18) 18 (29.51) 24 (14.12)
70–79 586 (37.93) 498 (37.9) 88 (38.1) 22 (36.07) 66 (38.82)
≥80 368 (23.82) 285 (21.69) 83 (35.93) 14 (22.95) 69 (40.59)
NYHA class
I 50 (3.32) 49 (3.83) 3 (0.01) 0.069 3 (1.69) – 0.008
II 139 (9.24) 116 (9.07) 23 (10.18) 7 (11.86) 16 (9.58)
III 1,091 (72.49) 925 (72.32) 166 (73.45) 49 (83.05) 117 (70.06)
IV 225 (14.95) 189 (14.78) 36 (15.93) 2 (3.39) 34 (20.36)
Device type, n (%)
CRT-D 561 (36.31) 501 (38.13) 60 (25.97) <0.001
CRT-P 984 (63.69) 813 (61.87) 171 (74.03)
Time to upgrade (days) – – – – 1,839 (697–2885) 1,396 (607-2433) 0.204
Etiology of cardiomyopathy, n (%)
Ischemic 854 (55.28) 742 (56.47) 112 (48.48) 0.024 41 (67.21) 71 (41.76) 0.001
Nonischemic 691 (44.72) 572 (43.53) 119 (51.52) 20 (32.79) 99 (58.24)
Comorbidities, n (%)
Diabetes mellitus 340 (22.01) 293 (22.3) 47 (20.35) 0.509 11 (18.03) 36 (21.18) 0.601
Hypertension 441 (28.54) 374 (28.46) 67 (29) 0.867 12 (19.67) 55 (32.35) 0.061
CABG 289 (18.71) 240 (18.26) 49 (21.21) 0.289 16 (26.23) 33 (19.41) 0.264
ECG variables
Sinus rhythm, n (%) 1,032 (66.84) 905 (68.93) 127 (54.98) <0.001 40 (65.57) 87 (51.18) 0.053
Atrial fibrillation, n (%)† 512 (33.16) 408 (31.07) 104 (45.02) 21 (34.43) 83 (48.82)
QRSmorphology (LBBB), n (%) 1,235 (81.84) 1,008 (78.87) 227 (98.27) <0.001 59 (96.72) 168 (98.82) 0.280
QRS duration (ms) 155.9± 23 153.5± 21.6 169.4± 25.7 <0.001 167.9± 24.7 169.9± 26.1 0.586
Medication, n (%)
Loop diuretics 1,443 (93.4) 1,223 (93.07) 220 (95.24) 0.222 59 (96.72) 161 (94.71) 0.526
ACEIs / ARA 1,346 (87.12) 1,159 (88.2) 187 (80.95) 0.002 51 (83.61) 136 (80) 0.538
Beta-blockers 1,005 (65.05) 865 (65.83) 140 (60.61) 0.125 47 (77.05) 93 (54.71) 0.002
MRAs 656 (42.46) 582 (44.29) 74 (32.03) 0.001 24 (39.34) 50 (29.41) 0.154
LVEF (%) 24.4± 9.5 23.9± 9.4 24.4± 9.5 <0.001 25.7± 9.5 27± 10.1 0.399
Note:Variables are expressed asmean± SD, unless indicated otherwise.
*refers to differences between the groups fromANOVA for continuous variables and from 𝜒2 tests for categorical variables.
†includes permanent, persistent, and paroxysmal atrial fibrillation (AF). ACEIs= angiotensin-converting enzyme inhibitors;
ARAs= angiotensin receptor blockers; CABG= coronary artery bypass grafting; CRT-D= cardiac resynchronization therapy-defibrillation; CRT-P= cardiac
resynchronization therapy-pacing; ECG = electrocardiogram; LBBB = left bundle branch block; LVEF = left ventricular ejection fraction; MRA =mineralo-
corticoid receptor antagonists; NYHA=NewYork Heart Association.
2.2 Endpoints
The primary endpoint was total mortality, which included cardiac
transplantation or implantation of a ventricular assist device. Sec-
ondary endpoints included: the composite endpoint of total mortality
or HF hospitalization, and the composite endpoint of total mortality or
unplanned hospitalization for major adverse cardiac events (MACEs),
which included hospitalization for HF, myocardial infarction, acute
coronary syndrome, and arrhythmia (ventricular tachycardia, ventric-
ular fibrillation, and atrial fibrillation). Stroke and pulmonary embolism
were not considered asMACEs. In composite endpoints, the first event
was used for censoring.Mortality datawere collected throughmedical
records and from interviews with patients’ caregivers. Clinical events
were collected every 6 months from the start of the study in 2000 by
investigators who had access to patient clinical records, but no access
to previously collected patient data or device-related data, which
are kept separate from clinical records. Events were adjudicated by
investigators at arbitrary intervals of 6 months using hospital records
and death certificates.
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TABLE 2 Event rates
Total mortality Total mortality or HF hospitalization
Total mortality or hospitalization for
MACEs
Overall CRT-D CRT-P Overall CRT-D CRT-P Overall CRT-D CRT-P
Events (n)
De novo 664 190 474 724 213 511 759 226 533
Upgrades 132 22 110 140 25 115 138 23 115
Incidence rates (%)
De novo 12.3 10.1 13.4 14.7 12.3 16.0 16.2 13.5 17.7
Upgrades 16.4 9.4 19.2 19.2 11.1 22.8 19.3 10.1 23.5
Note:Data are expressed as number of events and annualized event rates (%). Abbreviations as in Table 1.
TABLE 3 Propensity score-matched samples for de novo implants and upgrades
All De novo Upgrades P*
N 420 210 210
Sex (male), n (%) 315 (75) 158 (75.24) 157 (74.76) 0.910
Age, years 74.8± 10.1 74.6± 10 75± 10.3 0.663
≤59 34 (8.1) 16 (7.62) 18 (8.57) 0.553
60–69 84 (20) 43 (20.48) 41 (19.52)
70–79 168 (40) 90 (42.86) 78 (37.14)
≥80 134 (31.9) 61 (29.05) 73 (34.76)
NYHA class
I, II 50 (11.9) 27 (12.86) 23 (10.95) 0.681
III 302 (71.9) 147 (70) 155 (73.81)
IV 68 (16.19) 36 (17.14) 32 (15.24)
CRT-D, n (%) 114 (27.14) 57 (27.14) 57 (27.14) 1.000
Ischemic etiology, n (%) 210 (50) 106 (50.48) 104 (49.52) 0.845
ECG variables
Atrial fibrillation, n (%) 185 (44.05) 94 (44.76) 91 (43.33) 0.768
QRSmorphology (LBBB), n (%) 411 (97.86) 205 (97.62) 206 (98.1) 0.736
QRS duration (ms) 166.8± 23.6 167.2± 23.5 166.5± 23.8 0.759
Medication, n (%)
ACEIs / ARA 348 (82.86) 171 (81.43) 177 (84.29) 0.437
MRAs 145 (34.52) 73 (34.76) 72 (34.29) 0.918
Note: This shows the results of propensity score matching for de novo implants and upgrades. Note that the populations are well matched. Abbreviations as
in Table 1.
TABLE 4 Propensity scorematching and inverse probability weighting in upgrades to CRT-D versus upgrades to CRT-P
Total mortality Total mortality / HF hospitalization
Total mortality / Hospitalization
forMACEs
HR 95%CI P HR 95%CI P HR 95%CI P
Propensity scorematching
(N= 116)
0.57 0.33 0.99 0.045 0.57 0.33 0.97 0.037 0.51 0.30 0.88 0.015
Inverse probability weighting
(N= 226)
0.55 0.36 0.73 <0.001 0.56 0.34 0.79 <0.001 0.61 0.40 0.82 <0.001
Note:Results frompropensity scorematching and inverse probabilityweighting in upgraded patients, comparingCRT-D versus CRT-P. Results are expressed
as hazard ratios (HR) and 95% confidence intervals (CI). HF= heart failture. Other abbreviations as in Table 1.
2.3 Statistical analysis
Continuous variables are expressed as mean ± standard devia-
tion. Normality was tested using the Shapiro-Wilk test. Comparisons
between normally distributed continuous variables were made using
analysis of variance, and categorical variables were analyzed using 𝜒2
tests. Kaplan-Meier curves and the log-rank test were used to assess
observed cumulative survival. Cox proportional hazard models were
used to assess relative risks. Proportionality hypotheses were verified
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F IGURE 2 Primary and secondary endpoints in propensity-matched
samples. Kaplan-Meier survival curves for clinical outcomes according
whether patients had a de novo implant or an upgrade. CI= confidence
interval; CRT-D = cardiac resynchronization therapy-defibrillation;
CRT-P= cardiac resynchronization therapy-pacing; HF= heart failure;
MACE = major adverse cardiovascular events; psm HR = propensity
score-matched hazard ratio [Color figure can be viewed at wileyon-
linelibrary.com]
by visual examination of log (survival) graphs to ensure parallel slopes,
and by examining Schoenfeld residuals. Variables with a P < 0.10 on
univariable analyses were entered in multivariate models, and further
backward elimination was applied for the final multivariate models.
Statistical analyseswere performedusing Stata 14 (StataCorp, College
Station, TX,USA). A two-tailedP-value of<0.05was considered statis-
tically significant.
Propensity matching was undertaken for comparisons of de novo
and for upgrades. Variables were selected if they differed significantly
at baseline and if they emerged as predictors of total mortality. A 1:1
nearest-neighbor matching procedure within a caliper width of 0.01
was used. Each pair was used once and unpaired cases were excluded.
The standardized difference was used to assess the balance between
upgrades and de novo groups, and a difference of <10% was accepted
for matched cohorts.22 After matching, proportional hazards regres-
sion was used to compare survival outcomes in both groups. In the
comparison between CRT-D and CRT-P upgrades, an inverse probabil-
ity weighting approachwas used, using all patients upgraded to CRT as
reference.
3 RESULTS
3.1 Baseline characteristics in de novo implants
and upgrades
Of 1,349 patients scheduled for de novo device implantation, a suc-
cessful device implantation was achieved at the first attempt in 1,297
(96.1%) and at a second attempt in 17 (1.26%). Patients in whom a
first unsuccessful implantation was not followed by other implanta-
tion attempts (30 [2.22%]) and those referred for surgical epicardial
lead implantation (five [0.37%]) were excluded. Of 236 attempts at
device upgrade, 228 (96.6%) were successful at the first attempt and
three (1.27%) after a second attempt. One patient (0.42%) in whom a
first unsuccessful upgradewas not followed by other attempts and one
(0.42%)patientwhodied fromHFwithin2daysof deviceupgradewere
excluded. After device upgrade attempts, no patientswere referred for
surgical epicardial lead implantation. After ≥1 successful implantation
attempts, the total analytic population consisted of a total of 1,545
patients, 1,314 (85%) of whom were de novo implants and 231 (15%)
were upgrades. The rate of failures from de novo device implantation
or upgrades was uniformly distributed in the period 2001–2016 (data
not shown).
As shown in Table 1, the de novo and upgrade groups were well
matched for sex,NewYorkHeartAssociation (NYHA) class, comorbidi-
ties, and uptake of loop diuretics and beta-blockers. Upgraded patients
were on average 4 years older (P< 0.001) andweremore likely to have
atrial fibrillation (P < 0.001) and to receive CRT-P (P < 0.001). They
had a higher LV ejection fraction (LVEF, P < 0.001) and were less likely
to have ischemic cardiomyopathy (P = 0.024) and to have received
angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin recep-
tor blockers (ARAs) (P = 0.002) and mineralocorticoid receptor antag-
onists (MRAs) (P= 0.001).
3.2 Outcomes in de novo versus upgrade implants
Total mortality was 664/1,314 (50.5%; 12.3 per 100 person-years)
in the de novo group and 132/231 (57.1%; 16.4 per 100 person-
years) in the upgrade group over a maximum follow-up period of
16 years (median of 4.6 years, interquartile range [IQR]: 2.4–7.0;
4.7 years [IQR, 2.4–7.2] for de novo implants and 4.0 years [IQR:
2.0–5.7] for upgrades) (Table 2). In Kaplan-Meier survival analyses
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F IGURE 3 Subgroup analysis. Forest plot showing the risk of totalmortality according to accordingwhether patients had a de novo implant or an
upgrade. The horizontal lines indicate hazard ratios (HR) and95%confidence intervals (95%CI) for totalmortality for various subgroups. The verti-
cal line represents the results for the entire analysis. CRT-D= cardiac resynchronization therapy-defibrillator; CRT-P= cardiac resynchronization
therapy-pacemaker; LBBB= left bundle branch block; LVEF= left ventricular ejection fraction; NYHA=NewYork Heart Association [Color figure
can be viewed at wileyonlinelibrary.com]
(Figure 1), upgraded patients had a higher total mortality (P = 0.003)
and total mortality or HF hospitalization (P = 0.012), but total mortal-
ity or hospitalization forMACEswas comparable. Results of univariate
and multivariate Cox proportional hazards analyses are shown in the
Online Appendix. In propensity score-matched samples (Table 3), total
mortality (hazard ratio [HR]: 1.23, 95% confidence interval [CI] 0.95–
1.61), total mortality or HF hospitalization (HR: 1.17, 95% CI 0.91–
1.51), and total mortality or hospitalization for MACEs (HR: 1.02, 95%
CI 0.81–1.33) were comparable (HRs are for upgrades compared to
de novo implants). Multivariate Cox proportional hazards analyses also
showed no differences in these endpoints (seeOnline Appendix). Simi-
lar findings emerged in analyses of propensity score-matched samples
(Figure 2). As shown in subgroup analyses (Figure 3), total mortality
after upgrades compared tode novo implantswas significantly higher in
men, NYHA class III, CRT-P, nonischemic cardiomyopathy, nondiabetic
status, left bundle branch block, a QRS≥ 150ms, and a LVEF≤ 25%.
3.3 Baseline characteristics according to device
upgrade type
Of the 231 upgraded patients, 61 (26.4%) were upgraded to primary
prevention CRT-D and 170 (73.6%) to CRT-P. As shown in Table 1,
the groups were well matched for sex, comorbidities, atrial rhythm,
QRS duration and morphology, LVEF, and uptake of ACEIs/ARAs and
MRAs. Compared to CRT-P upgrade patients, CRT-D upgrade patients
were 4.9 years younger (P < 0.001), had a better NYHA class (86.4%
and 90.4% in NYHA class III or IV, respectively; P = 0.008), and were
more likely to have ischemic cardiomyopathy (P = 0.001). In addi-
tion, CRT-D upgrade patients had a higher uptake of beta-blockers
(P= 0.002).
3.4 Outcomes according to device upgrade type
In Kaplan-Meier survival analyses (Figure 3), CRT-D upgrades had a
lower total mortality (P = 0.002), total mortality or HF hospitaliza-
tion (P = 0.001), and total mortality or hospitalization for MACEs
(P < 0.001). We undertook a two-step procedure to correct variable
imbalance. First, we undertook propensity score matching between de
novo implants and upgrades (Table 3), using the variables either dif-
fered significantly at baseline or that emerged as predictors of primary
endpoint, amongwhich age emerged as a significant predictor. Second,
we undertook both inverse probability weighting and propensity score
matching between CRT-D and CRTP upgrades in order to correct for
age and other variables (Table 4). After inverse probability weighting
(Figure 4), total mortality (HR: 0.55, 95%CI 0.36–0.73), total mortality
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F IGURE 4 Primary and secondary endpoints according to device
type at upgrade procedure. Kaplan-Meier survival curves for clin-
ical outcomes according to device type at the time of upgrade.
CI = confidence interval; CRT-D = cardiac resynchronization therapy-
defibrillation; CRT-P = cardiac resynchronization therapy-pacing;
HF = heart failure; MACE = major adverse cardiovascular events;
inverse probability weighting hazard ratio (ipw HR) for CRT-D com-
pared with CRT-P upgrades [Color figure can be viewed at wileyon-
linelibrary.com]
or HF hospitalization (HR: 0.56, 95%CI 0.34–0.79), and total mortality
or hospitalization forMACEs (HR: 0.61, 95%CI 0.40–0.82) were lower
after CRT-D than after CRT-P (all P< 0.001). The findings of multivari-
ate Cox proportional hazards analyses and inverse probability weight-
ing were similar. Cardiac mortality was lower in CRT-D upgrades (log-
rank P = 0.005), but no differences in noncardiac mortality emerged
(log-rank P= 0.139) (Figure 5).
F IGURE 5 Cardiac and noncardiac mortality according to device
type at upgrade procedure. Kaplan-Meier survival curves for cardiac
and non-cardiac mortality according to device type at the time of
upgrade. CRT-D = cardiac resynchronization therapy-defibrillation;
CRT-P = cardiac resynchronization therapy-pacing; HF = heart fail-
ure;MACE=major adverse cardiovascular events [Color figure can be
viewed at wileyonlinelibrary.com]
To explore the effect of date of implantation on outcomes, we first
included different year dummies on survival analyses and found that
date of implantation did not emerge as a predictor of any of the end-
points. We also created a dichotomous variable, with year 2014 as
the “cut-off.” In this analysis, no significant differences in outcomes
emerged.Moreover, therewas no interaction betweendate of upgrade
and device type at the upgrade procedure (CRT-D vs CRT-P; data not
shown).
4 DISCUSSION
This is the largest study with the longest follow-up of patients under-
going upgrading from pacemakers to CRT-D or CRT-P in the context
of primary prevention, i.e., patients with no history of sustained ven-
tricular arrhythmias before the initial pacemaker implant or the CRT
upgradeprocedure.We found that, after covariate adjustment, the risk
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of total mortality, total mortality or HF hospitalization, and total mor-
tality or hospitalization for MACEs was similar in upgraded patients
compared to patients undergoing de novoCRT implantation.Moreover,
outcomes were consistently better after an upgrade to CRT-D rather
than to CRT-P.
4.1 De novo implants versus upgrades
Vamos et al. recently compared 375 de novo CRT-D implants and 177
CRT-D upgrade procedures.23 Over a mean follow-up of 3.1 years,
upgrades were associated with a higher mortality. Importantly, how-
ever, the patient population included upgrades from ICD to CRT-D
and a large proportion of patients (42%) were upgraded to CRT-D for
secondary prevention, compared to only 11.1% in the de novo group.
Therefore, this study does not address upgrades in the context of
primary prevention, but a heterogeneous population with a preexist-
ing arrhythmic risk. In contrast, we found that after propensity score
matching of “primary prevention” patients, outcomes were compara-
ble after de novo implants and upgrades.
4.2 CRT-D versus CRT-P upgrade
An argument for upgrading to CRT-P is that LV dysfunction in patients
with pacemakers is likely to be due to RV pacing and that CRT should
correct it, perhaps improving LV function to a degree that the LVEF
improves above the cut-off of 35% thatwould obviate ICD therapy. For
upgrading toCRT-D is that patientswith pacemakers and a LVEF<35%
fall under the indications for an ICD, with the exception that they
already have a pacemaker. Pivotal to this question is whether CRT-D
is superior to CRT-P in patients without prior ventricular arrhythmias.
In a recent observational study of 199 pacemaker patients with no
history of sustained ventricular arrhythmias, Barra et al. included
104 upgrades to CRT-P and 95 upgrades to CRT-D. Over a mean
follow-up of 5.5 years, three of 104 (2.9%) patients in the CRT-P arm
had a primary arrhythmic death (6.2 sudden arrhythmic deaths per
1,000 patient-years). The authors concluded that patientswith pacing-
induced cardiomyopathy and no prior ventricular arrhythmias who
are upgraded to CRT may not derive any significant benefit from the
addition of a defibrillator.24 In contrast, we found that CRT-D upgrade
was consistently superior to CRT-P upgrades with respect to the three
main endpoints, even after inverse probability weighting. In addition,
analysis of cause of death showed that this was predominantly due
to a lower cardiac rather than noncardiac death. Our findings have
emerged in the context of the ongoing BUDAPEST CRT trial,25 which
will compare upgrading from pacemakers to ICD or CRT-D, but not
from pacemakers to CRT-P or CRT-D. Currently, there are no planned
trials addressing whether CRT-D is superior to CRT-P at the time of
upgrading from pacemakers in the context of primary prevention.
4.3 Limitations
This is nonrandomized and observational study and, therefore, our
findings should be interpreted with caution. The groups were signifi-
cantly unbalanced. In particular, there was a specific bias toward CRT-
P in nonischemic cardiomyopathy and CRT-D in ischemic cardiomy-
opathy. This is a known bias. As this study was not randomized, there
will also be multiple unknown biases which may influence survival and
other outcomes. Unfortunately, LV function was not systematically
coded prior to implantation of conventional pacemakers. Given that
some patients underwent the original pacemaker implantation before
the advent ofCRT, it is possible that, in contrast to our current practice,
a proportionmay not have had an echocardiogram. Some patients may
have had LV dysfunction and/or HF at the time of pacemaker implan-
tation. In addition, the serial uptake of RV pacing was not system-
atically collected and reduction of RV pacing was not systematically
attempted, as this study precedes the development of appropriate
algorithms. In addition, programming and changes thereof throughout
the follow-up period, which were not systematically addressed, could
also impact on outcomes. The lack of systematic collection of therapies
(antitachycardia pacing and shocks) delivered is further limitation.
5 CONCLUSIONS
We have found that in patients with HF and preexisting pacemakers,
upgrading to CRT is associated with a similar long-term risk of mor-
tality and HF hospitalization to patients undergoing de novo CRT. In
upgraded patients, CRT-D was associated with lower mortality than
CRT-P.
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